Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Atrial fibrillation (AF) is the most common cardiac arrhythmia and has a rising prevalence due to an aging population. AF increases the patient's risk of hospitalization, heart failure and stroke and results into deterioration of quality of life. Treatment of symptomatic AF consists of either antiarrhythmic medication or a pulmonary vein isolation (PVI) catheter ablation. However, lots of patients experience recurrence of AF in the first year after PVI.
Previous studies showed that PVI outcomes depend on the presence of different treatable risk factors that influence the substrate for AF. Those risk factors include obesity, hypertension, cholesterol, diabetes mellitus, alcohol use, smoking and obstructive sleep apnea syndrome. However, research into the effect of treatment of those risk factors mainly consists of observational studies. Currently, it is not clear to what extent patients will benefit from comprehensive risk factor treatment prior to PVI in terms of ablation success and quality of life.
The aim of the current randomized controlled trial is to determine the effect of a nurse-led, technology-supported, personalized care pathway on hospital admissions for cardioversions and re-ablation in patients with AF that are referred for ablation.
Patients included in this study will be randomized to either the intervention group receiving the comprehensive risk treatment before PVI or the control group receiving standard usual care. Patients in the intervention group will visit the specialized AF nurse outpatient clinic and receive a personalized treatment plan (with a maximal duration of 6 months) including lifestyle interventions and medication. This includes sleep apnea screening with a Home Sleep Apnea Test (WatchPAT). Patients will also use the VitalHealth Engage platform. The digital platform can be used at home to report AF complaints, send home measurement and complete questionnaires. Furthermore, it supports the nurse in administering effective lifestyle changes by offering the patient personalized content and education.
Both study groups will be followed up to 12 months after ablation, during which hospital admissions for cardioversion and re-ablation are evaluated. At baseline, AFEQT, EQ5D and TBQ quality of life questionnaires will be performed. The questionnaires will be repeated prior to ablation, at 3 and 12 months after ablation. At baseline, pre-ablation and after 12 months laboratory tests (such as cholesterol) will be performed to evaluate adherence to lifestyle interventions.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Risk intervention group | Experimental | Comprehensive risk factor management at specialized AF outpatient clinic concerning blood pressure, cholesterol, glycaemic control, physical inactivity, weight control, smoking, alcohol intake and sleep apnea. |
|
| Control group | Active Comparator | Standard of care. Treatment by cardiologist conform existing guidelines. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Comprehensive risk factor treatment | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of hospital visits for cardioversion of AF and re-ablations | All events that occur between study inclusion and up to 12 months after ablation, including events prior to ablation. This means that events during the risk factor treatment period are also included | Up to 12 months after ablation or finishing risk treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Number of hospital visits for cardioversion of AF | All events that occur between study inclusion and up to 12 months after ablation, including events prior to ablation. | Up to 12 months after ablation or finishing risk treatment |
| Number of reablations |
| Measure | Description | Time Frame |
|---|---|---|
| Medical costs | An economic evaluation will be performed by examining all study intervention and AF related hospital costs. The total costs for both study groups will be compared | Up to 12 months after ablation or finishing risk treatment |
| Cost-effectiveness ratio |
Inclusion Criteria:
Patients with paroxysmal or persistent symptomatic atrial fibrillation referred for initial catheter ablation
Patients should be native Dutch speakers
Patients are able to use the VitalHealth Engage platform on their own preferred device (tablet, mobile phone, computer)
The patient has at least one of the following risks
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lukas Dekker, MD, PhD | Catharina Ziekenhuis Eindhoven | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Catharina Ziekenhuis | Eindhoven | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37000245 | Derived | Vermeer J, Vinck T, de Louw B, Slingerland S, van 't Veer M, Regis M, Jansen JM, van den Heuvel E, Dekker L. Improving outcomes of AF ablation by integrated personalized lifestyle interventions: rationale and design of the prevention to improve outcomes of PVI (POP) trial. Clin Res Cardiol. 2023 Jun;112(6):716-723. doi: 10.1007/s00392-023-02185-5. Epub 2023 Mar 31. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| D040242 | Risk Reduction Behavior |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Standard of care | Other | Standard usual care: Treatment by cardiologist conform existing guidelines |
|
All events that occur between study inclusion and up to 12 months after ablation, including events prior to ablation. |
| Up to 12 months after ablation or finishing risk treatment |
| The composite of mortality, stroke or hospitalization for heart failure or acute ischemic events. | Number of events. All events that occur between study inclusion and up to 12 months after ablation, including events prior to ablation. | Up to 12 months after ablation |
| All-cause mortality | Any deaths occurring during the study. | Up to 12 months after ablation or finishing risk treatment |
| Number of strokes | All events that occur between study inclusion and up to 12 months after ablation, including events prior to ablation. | Up to 12 months after ablation or finishing risk treatment |
| Hospitalizations for heart failure or acute ischemic events | Number of events. All events that occur between study inclusion and up to 12 months after ablation, including events prior to ablation. | Up to 12 months after ablation or finishing risk treatment |
| Quality of Life - EQ-5D | Quality of Life as measured by the EuroQol 5 Dimensions (EQ-5D) questionnaire. The questionnaire compromises 5 dimensions describing different aspects of health and an overall health perception. The 5 dimensions can each be scored from level 1 to 5. Lower levels correspond with higher quality of life and higher levels correspond with lower quality of life. Overall health perception is scored with a visual analogue scale (VAS) ranging from 0 to 100, with lower values corresponding with worse outcomes and higher values corresponding to better outcomes. | Up to 12 months after ablation or finishing risk treatment |
| Quality of Life - Atrial Fibrillation Effect on QualiTy of life survey (AFEQT) | Quality of Life as measured by the AFEQT questionnaire. The questionnaire contains 21 questions on a seven point Likert scale. Overall score ranges from 0 to 100. A score of 0 corresponds with complete disability, while a score of 100 corresponds with no disability. | Up to 12 months after ablation or finishing risk treatment |
| Treatment burden - Treatment Burden Questionnaire (TBQ) | Treatment burden is the perception of cumulative work a patient has to perform to manage their health. The TBQ consists out of 15 items with a ten point rating scale. A higher score corresponds to a greater burden, while a lower score corresponds with a lower burden. | Up to 12 months after ablation or finishing risk treatment |
| Rate of Success for ablation | The ablation is considered to be successful if patients could stop their antiarrhythmics after 3 months (the blanking period) without recurrent arrhythmia. If patients develop recurrent arrhythmia and had to restart antiarrhythmics after the blanking period, the index ablation is considered unsuccessful. | From 3 months after ablation up to 12 months after ablation |
| Number of Cancellations of index ablation | Patients might experience absence of AF complaints after they have had effective treatment of their risk factors. The treating cardiologist might decide to cancel the index ablation if patients do not experience any AF complaints. | Up to 12 months after finishing risk factor treatment |
Cost-effectiveness ratio will be analyzed by aggregating number of cardioversions and number of re-ablations and AF related medical costs. The cost-effectiveness ratio is the net costs per prevented cardioversion or re-ablation. |
| Up to 12 months after ablation or finishing risk treatment |
| Patient value | Patient value will be assessed from a Value-Based Healthcare perspective. This will be done by dividing patient relevant outcomes, the quality of life as assessed by EQ-5D and AFEQT, through the costs per patient to achieve these outcomes. | Up to 12 months after ablation or finishing risk treatment |
| Ablation - procedure times | Procedure time and fluoroscopy time | During ablation |
| Ablation - DAP | Dose area product (DAP) during ablation, presented in mGy·cm2 | During ablation |
| Weight target achievement | Weight (in kg) will be measured at follow-up to determine whether patients did reach the target of losing 10% of total body weight. | Up to 12 months after finishing risk factor treatment |
| Blood pressure target achievement | Blood pressure (in mmHg) will be measured at follow-up to determine whether the target of <130/80 mmHg was reached. | Up to 12 months after finishing risk factor treatment |
| Success of treatment of sleep apnea | The apnea-hypopnea index (AHI) is used to determine the effect of sleep apnea treatment. AHI is determined at the start and end of sleep apnea treatment | Up to 12 months after finishing risk factor treatment |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D001519 | Behavior |